Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exploring the controversial role of PI3K signalling in CD4+ regulatory T (T-Reg) cells.
Poli A, Fiume R, Mongiorgi S, Zaurito A, Sheth B, Vidalle MC, Hamid SA, Kimber S, Campagnoli F, Ratti S, Rusciano I, Faenza I, Manzoli L, Divecha N. Poli A, et al. Among authors: sheth b. Adv Biol Regul. 2020 May;76:100722. doi: 10.1016/j.jbior.2020.100722. Epub 2020 Apr 23. Adv Biol Regul. 2020. PMID: 32362560 Review.
"Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia".
Ratti S, Evangelisti C, Mongiorgi S, De Stefano A, Fazio A, Bonomini F, Follo MY, Faenza I, Manzoli L, Sheth B, Vidalle MC, Kimber ST, Divecha N, Cocco L, Fiume R. Ratti S, et al. Among authors: sheth b. Front Oncol. 2021 May 24;11:678824. doi: 10.3389/fonc.2021.678824. eCollection 2021. Front Oncol. 2021. PMID: 34109125 Free PMC article. Review.
Nuclear Phosphoinositides: Their Regulation and Roles in Nuclear Functions.
Fiume R, Faenza I, Sheth B, Poli A, Vidalle MC, Mazzetti C, Abdul SH, Campagnoli F, Fabbrini M, Kimber ST, Mariani GA, Xian J, Marvi MV, Mongiorgi S, Shah Z, Divecha N. Fiume R, et al. Among authors: sheth b. Int J Mol Sci. 2019 Jun 19;20(12):2991. doi: 10.3390/ijms20122991. Int J Mol Sci. 2019. PMID: 31248120 Free PMC article. Review.
Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.
Roghanian A, Teige I, Mårtensson L, Cox KL, Kovacek M, Ljungars A, Mattson J, Sundberg A, Vaughan AT, Shah V, Smyth NR, Sheth B, Chan HT, Li ZC, Williams EL, Manfredi G, Oldham RJ, Mockridge CI, James SA, Dahal LN, Hussain K, Nilsson B, Verbeek JS, Juliusson G, Hansson M, Jerkeman M, Johnson PW, Davies A, Beers SA, Glennie MJ, Frendéus B, Cragg MS. Roghanian A, et al. Among authors: sheth b. Cancer Cell. 2015 Apr 13;27(4):473-88. doi: 10.1016/j.ccell.2015.03.005. Cancer Cell. 2015. PMID: 25873171 Free article.
148 results